CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
20mg daily citalopram +1 moredrug
Likely dose
Citalopram 20 mg daily × 16 weeksAI-extracted
Key inclusion· 5
  • ✓Gene-positive HD test or clinical HD diagnosis with abnormal motor signs (UHDRS diagnostic confidence ≥1)
  • ✓Age 18–75 years
  • ✓Mild-stage HD: Shoulson and Fahn Scale stage 1 or 2
  • ✓Evidence of mild executive dysfunction: complaints of poor cognition, mild functional decline, or objective evidence of decline from baseline
Key exclusion· 8
  • ✕Current major depression significant by investigator judgment or current suicidal ideation
  • ✕Unstable or severe psychiatric disease: schizophrenia, bipolar disorder, dementia, delirium, severe anxiety, or substance abuse/dependence
  • ✕Current SSRI or other depression treatment, or SSRI use within 14 days
  • ✕St. John's wort use within 14 days

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00271596
NCT00271596Phase 2Completed
CompareCT.gov

A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)

University of Iowa·interventional·Posted Jan 2, 2006·Updated Mar 13, 2013

In Brief

A Phase 2 clinical trial evaluating 20mg daily citalopram and Placebo for Huntington Disease and 2 related conditions. Completed, enrolled 33 participants across 3 sites.

Detailed Summary

This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims: 1. To determine the effect of citalopram compared to placebo in patients with early HD on executive function and other outcome variables including functional measures (health-related quality of life, work productivity, and self-reported attention), motor performance, and psychiatric status, 2. To study the relationship between executive function and functional status in patients with early HD after selective serotonin reuptake inhibitor (SSRI) treatment, and 3. To examine the effect of citalopram treatment on volumetric and metabolic (i.e, N-acetyl-aspartate concentration) measures in the neostriatum among patients with recently diagnosed Huntington's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease, Chorea, Executive Dysfunction
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS), Cure Huntington's Disease Initiative (CHDI), University of Rochester, Mayo Clinic

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2, 2006
Enrollment StartNov 1, 2005
Primary CompletionApr 1, 2011
Study CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 20.5 years ago

Interventions

20mg daily citalopramdrug

a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks

Placebodrug

a daily matching placebo administered over 16 weeks